Aspen Aerogels, Inc. (ASPN) Key Metrics

NYSE: ASPNValuation, returns, debt and efficiency ratios over 10 years.

ASPN valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$430.7M
Enterprise value
$444.8M
P/E (TTM)
—
Forward P/E
714.3
PEG ratio
—
Price / sales
2.1
10-yr median 1.7
Price / book
2.4
10-yr median 1.3
EV / EBITDA
65.4
Dividend yield
—
Beta
3.06

ASPN key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

ASPN valuation Price multiples at each fiscal year-end price.

Price / sales−59.1%
0.9
2025 · hover or tap a bar for each year
2016: 0.8 (−28.7%)2017: 1.0 (+26.0%)2018: 0.5 (−52.6%)2019: 1.3 (+176.9%)2020: 4.4 (+227.2%)2021: 12.5 (+183.8%)2022: 3.8 (−69.4%)2023: 4.6 (+20.3%)2024: 2.1 (−54.1%)2025: 0.9 (−59.1%)
20162025
Price / book−36.0%
1.0
2025 · hover or tap a bar for each year
2016: 0.8 (−27.4%)2017: 1.1 (+36.7%)2018: 0.7 (−36.4%)2019: 3.2 (+340.5%)2020: 6.5 (+104.7%)2021: 11.8 (+81.9%)2022: 1.0 (−91.2%)2023: 2.2 (+116.5%)2024: 1.6 (−30.9%)2025: 1.0 (−36.0%)
20162025
Free cash flow yield+2.3 pts
−2.0%
2025 · hover or tap a bar for each year
2016: −14.4% (−2.5 pts)2017: −9.4% (+5.0 pts)2018: −24.2% (−14.8 pts)2019: −1.7% (+22.5 pts)2020: −3.0% (−1.3 pts)2021: −2.1% (+0.9 pts)2022: −58.7% (−56.6 pts)2023: −19.9% (+38.8 pts)2024: −4.3% (+15.6 pts)2025: −2.0% (+2.3 pts)
20162025

ASPN valuation history

Fiscal year-endToday10-year median

ASPN returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

ASPN debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

ASPN cash returned to shareholders

DividendsBuybacksFree cash flow

ASPN price vs earnings per share

Share price at year-endEPS (right axis)

ASPN key metrics

2016–2025
Aspen Aerogels, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$233.9M$954.0M$1.10B$464.1M$1.52B$440.2M$187.0M$50.6M$114.1M$95.6M
Enterprise value$220.8M$930.5M$1.09B$302.2M$1.45B$432.1M$191.8M$51.4M$107.2M$77.5M
P/E ratio—71.3————————
Price / sales0.92.14.63.812.54.41.30.51.00.8
Price / book1.01.62.21.011.86.53.20.71.10.8
Price / operating cash flow7.120.9————————
EV / sales0.82.14.62.512.04.31.40.51.00.7
EV / EBITDA—18.8————————
Earnings yield−166.5%1.4%−4.2%−8.0%−1.8%−2.7%−2.5%−68.1%−16.9%−12.6%
Free cash flow yield−2.0%−4.3%−19.9%−58.7%−2.1%−3.0%−1.7%−24.2%−9.4%−14.4%
Dividend yield———21.0%—0.3%——0.0%0.0%
Shareholder yield (dividends + buybacks)——0.0%21.5%0.2%0.6%0.3%1.1%0.3%0.2%
Share price at fiscal year-end$2.83$11.88$15.78$11.79$49.79$16.69$7.76$2.13$4.88$4.13
Per share
Revenue per share$3.28$5.64$3.44$3.09$4.00$3.80$5.78$4.40$4.77$5.09
Earnings per share−$4.71$0.17−$0.66−$0.94−$0.92−$0.45−$0.20−$1.45−$0.83−$0.52
Operating cash flow per share$0.40$0.57−$0.61−$2.40−$0.61−$0.38−$0.04−$0.36−$0.20−$0.02
Free cash flow per share−$0.06−$0.51−$3.14−$6.92−$1.06−$0.51−$0.13−$0.52−$0.46−$0.60
Cash per share$1.90$2.75$2.01$7.15$2.52$0.63$0.15$0.14$0.46$0.78
Book value per share$2.85$7.65$7.03$11.37$4.22$2.57$2.45$2.96$4.32$4.99
Tangible book value per share$2.85$7.65$7.03$11.37$4.22$2.57$2.45$2.96$4.32$4.99
Dividends per share———$2.48—$0.05——$0.00$0.00
Capex per share$0.45$1.07$2.53$4.52$0.45$0.13$0.09$0.15$0.26$0.57
Debt per share$1.74$2.46$2.00$3.03$0.50$0.32$0.35$0.18$0.16$0.00
Shares outstanding82.7M80.3M69.4M39.4M30.4M26.4M24.1M23.7M23.4M23.1M
Change in shares outstanding+2.9%+15.7%+76.4%+29.3%+15.4%+9.5%+1.5%+1.5%+1.1%+0.7%
Returns & profitability
Return on equity (ROE)−91.6%2.4%−9.8%−12.9%−28.4%−18.7%−7.4%−40.2%−17.8%−10.1%
Return on invested capital (ROIC)−10.0%9.5%−10.1%−18.2%−50.6%−27.6%−16.6%−32.5%−15.8%−9.5%
Return on assets (ROA)−59.8%1.7%−6.8%−9.0%−19.9%−11.8%−4.7%−30.9%−14.9%−8.8%
Return on tangible assets−95.8%1.5%−6.5%−5.8%−15.2%−12.2%−4.6%−34.8%−15.6%−8.9%
Free cash flow margin−1.7%−9.0%−91.3%−224.0%−26.6%−13.3%−2.3%−11.7%−9.6%−11.7%
Income quality (OCF / net income)—3.41————————
Financial health
Total debt$143.7M$197.4M$138.8M$119.4M$15.2M$8.3M$8.5M$4.2M$3.8M$39,000
Cash & short-term investments$156.9M$220.9M$139.7M$281.3M$76.6M$16.5M$3.6M$3.3M$10.7M$18.1M
Net debt−$13.2M−$23.5M−$951,000−$161.9M−$61.3M−$8.2M$4.8M$854,000−$6.9M−$18.0M
Debt / equity0.610.320.280.270.120.120.140.060.040.00
Debt / assets0.350.220.200.190.080.090.080.040.030.00
Net debt / EBITDA—−0.47————————
Current ratio3.903.723.414.683.073.381.501.612.212.77
Quick ratio3.293.292.914.402.742.441.221.301.802.06
Interest coverage-4.84.9-9.2-177.3-177.3-89.9-34.9-64.7-103.4-76.3
Working capital$180.0M$299.3M$188.2M$290.7M$75.6M$33.2M$15.3M$14.2M$26.1M$32.1M
Invested capital$222.4M$591.2M$487.1M$285.5M$67.1M$59.7M$63.8M$71.1M$94.0M$97.5M
Tangible asset value$235.5M$614.7M$488.1M$447.4M$128.4M$67.9M$59.0M$70.3M$100.9M$115.6M
Net current asset value$70.9M$129.0M$51.3M$173.7M$57.6M$17.6M$1.3M$8.5M$24.8M$31.1M
Graham number—$5.36————————
Graham net-net per share$0.38$0.57−$0.05$3.55$1.42$0.20−$0.51−$0.11$0.53$0.80
Capital allocation
Dividends paid———$97.5M—$1.2M——$0$0
Share buybacks (net)——$420,000$2.4M$2.7M$1.2M$470,000$551,000$391,000$200,000
Capex / revenue13.8%19.1%73.5%146.3%11.3%3.4%1.5%3.4%5.5%11.2%
Capex / operating cash flow113.9%189.4%————————
Capex / depreciation0.833.8311.4519.301.460.330.210.330.571.34
Stock-based compensation / revenue3.2%2.8%4.6%7.7%4.3%5.0%2.7%4.1%4.6%4.5%
R&D / revenue4.9%4.0%6.9%9.4%9.4%8.7%6.0%6.1%5.5%4.5%
SG&A / revenue31.0%23.6%37.6%32.1%32.1%27.4%23.0%31.5%28.3%24.8%
Efficiency
Days sales outstanding97.272.297.4116.754.287.375.791.572.459.1
Days of inventory on hand69.658.762.056.441.046.626.032.342.837.5
Days payables outstanding46.764.6106.2117.937.238.240.345.946.645.9
Cash conversion cycle (days)120.066.353.155.258.095.661.378.068.650.7
Receivables turnover3.765.063.753.136.734.184.823.995.046.17
Payables turnover7.825.653.443.109.809.559.057.967.847.95
Inventory turnover5.256.225.896.478.907.8414.0611.308.549.73
Asset turnover0.420.570.350.290.871.001.380.940.860.86
Average receivables$72.2M$89.5M$63.7M$38.9M$18.1M$24.0M$28.9M$26.2M$22.1M$19.1M
Average payables$28.8M$47.7M$52.9M$36.1M$11.4M$9.0M$12.5M$11.5M$11.9M$11.9M
Average inventory$42.9M$43.4M$30.9M$17.3M$12.5M$10.9M$8.0M$8.1M$10.9M$9.7M
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Computed from ASPN's annual financial statements (latest annual report filed March 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

ASPN valuation and financial ratios

Aspen Aerogels earned a return on equity of −91.6% and a return on invested capital of −10.0% in fiscal 2025. It ended the year with $143.7 million of debt and $156.9 million in cash and short-term investments, a net cash position of $13.2 million. The share count rose 257.2% from 23.1M to 82.7M over 9 years.

See the ASPN income statement, the ASPN chart for price history, or the ASPN stock overview for the latest quote and news.

ASPN key metrics FAQ

What is Aspen Aerogels's return on equity?

Aspen Aerogels's return on equity (ROE) was −91.6% in fiscal 2025: net income of -$389.6 million on average shareholders' equity of $425.1 million.

What is Aspen Aerogels's ROIC?

Aspen Aerogels's return on invested capital was −10.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Aspen Aerogels have?

Aspen Aerogels had total debt of $143.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.61 and more cash than debt.

What is Aspen Aerogels's free cash flow yield?

Aspen Aerogels generated -$4.6 million of free cash flow in fiscal 2025, a free cash flow yield of −2.0% on its market value at year-end ($233.9 million).

What is Aspen Aerogels's current ratio?

Aspen Aerogels's current ratio was 3.90 at the end of fiscal 2025: current assets were 3.90 times current liabilities.

Specialty Chemicals key metrics